De Zeng - Concepedia

Author

De Zeng

Cancer Hospital of Shantou University Medical College ORCID

Also Known As

D. Zeng, D.-W. Zeng, Da-Hai Zeng, Danfan Zeng, Danfeng Zeng, Dashuang Zeng, De ZENG, De Zeng, Defan Zeng, Defeng Zeng

Publications

911

Citations

H-Index

Concepts

All Affiliations

Cancer Hospital of Shantou University Medical College Shantou University First Affiliated Hospital of Shantou University Medical College Shantou University Medical College University of Groningen

About

De Zeng is an author at Cancer Hospital of Shantou University Medical College specializing in medicine, breast cancer, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	470
2	Cell Biology	8	8	373
3	Immunology	3	3	150
4	Engineering	2	2	53
5	Molecular Biology	1	1	10

De Zeng

Publications

858

Citations

H-Index

Page 1

	Year	Citations
<i>RETRACTED:</i> Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin <i>via</i> direct downregulation of MCAM in triple‐negative breast cancer cells De Zeng, Yuanke Liang, Yingsheng Xiao, International Journal of Cancer Breast OncologyUnique Emt ActivatorMedicineEmt ProgramCancer Cell Biology	2020	90
Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells Yingsheng Xiao, De Zeng, Yuanke Liang, Cancer Letters Breast OncologyDirect TargetImmunologyTnbc CellsCancer Biology	2018	76
Prognostic values of distinct CBX family members in breast cancer Yuanke Liang, Haoyu Lin, Chunfa Chen, Oncotarget	2017	75
MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial–mesenchymal transition, decreased ERα expression and AKT activation Yuanke Liang, De Zeng, Yingsheng Xiao, Cancer Letters Breast OncologyTamoxifen ResistanceMedicineErα ExpressionBreast Cancer Cells	2016	64
CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer Yuanke Liang, Ze-kun- Deng, Mu-tong CHEN, Frontiers in Oncology Breast OncologyImmune Infiltration AssociatedImmunologyPathologyImmunotherapy	2021	58
FoxM1 is a promising candidate target in the treatment of breast cancer Xiaofeng Lu, De Zeng, Weiquan Liang, Oncotarget	2017	49
GATA3 and TRPS1 are distinct biomarkers and prognostic factors in breast cancer: database mining for GATA family members in malignancies Haoyu Lin, De Zeng, Yuanke Liang, Oncotarget Breast OncologyEngineeringDatabasesPathologyCancer Biology	2017	43
Notch3 inhibits cell proliferation and tumorigenesis and predicts better prognosis in breast cancer through transactivating PTEN Yong‐Qu Zhang, Yuanke Liang, Yang Wu, Cell Death and Disease	2021	43
Notch3 inhibits epithelial–mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression Haoyu Lin, Yuanke Liang, Xiaowei Dou, Oncogenesis	2018	42
CD146 interaction with integrin β1 activates LATS1-YAP signaling and induces radiation-resistance in breast cancer cells Yuanke Liang, Xiaoling Zhou, Qin Xie, Cancer Letters Breast OncologyIntegrin β1Integrin β1 ActivityCancer BiologyTumor Biology	2022	35

Page 1